Patients currently treated with triptans and less than very satisfied with their acute migraine therapy experienced a statistically significant and clinically relevant increase in satisfaction with therapy and enhanced confidence in treatment after use of Sumavel DosePro for up to 4 migraine attacks.

One hundred and eighty‐eight subjects with psoriasis of the scalp voluntarily participated in this multicenter, randomized, double‐blind, active, and placebo‐controlled study to evaluate the safety and efficacy of clobetasol propionate foam 0.05% (CP foam) relative to clobetasol propionate solution 0.05% (CP solution, Temovate® scalp application). Adult male and female subjects with moderate to severe disease were assigned to one of four treatment groups in a 2 : 1 : 2 : 1 ratio (CP foam : placebo foam : CP solution : placebo solution). Moderate to severe disease was defined as involvement of at least 10% of the scalp and a minimum score of 2 (0, none; 1, mild; 2, moderate; 3, severe; 4, very severe) for each of the primary signs of psoriasis (erythema, scaling, plaque thickness). Subjects applied study medication to the entire scalp twice daily for 14 consecutive days and were required to use DHS shampoo. No other therapy to the scalp was allowed. Pruritus, scaling, erythema, and plaque thickness were evaluated on days 0, 7, and 15, and after 2 weeks off treatment on day 28. In addition, both the investigator and subject evaluated the global response to treatment at days 15 and 28 using a seven‐point grading scale (completely clear, almost clear, marked improvement, moderate improvement, slight improvement, no change, or worse). The number of subjects who were ‘‘completely clear’' or ‘‘almost clear’' (> 90% clearing) were lumped together to determine treatment success. Safety was assessed via standard clinical laboratory panels (chemistry, hematology, urinalysis), physical examination, vital signs, and reported adverse events. In addition to the clinical study, the potency of CP foam relative to five other dosage forms of CP, as well as to betamethasone valerate lotion 0.1%, was determined in 24 healthy male and female subjects using a modification of the new vasoconstrictor procedure. 1Products were randomly applied to 3.14 cm 2sites on the ventral forearms at a dose of 10 μL, covered with a nonocclusive guard, then removed after 3 h with dry, cotton swabs. Skin color was measured at − 1, 1, 4, 8, 12, 24, and 30 h using a chromameter (Minolta, Ramsey, NJ). Vasoconstrictor potency was assessed from the area‐under‐the‐skin‐blanching curve (AUC) using the a* scale output of the chromameter. The percutaneous absorption of CP from both the foam and solution formulations was determined using the cadaver skin assay. 2Each product was applied to multiple sections of skin at a dose of 6–8 mg/cm 2, and the solution bathing the dermis was sampled at intervals and analyzed for CP content by high performance liquid chromatography. Investigators: Edwin A. Bronsky, md, Intermountain Clinical Research, Salt Lake City, UT; Frank E. Dunlap, md, Argus Research, Inc., Tuscon, AZ; Holly B. Faust, md, Indiana University, Indianapolis, IN; David P. Fivenson, md, Henry Ford Hospital, Detroit, MI; Alan M. Heller, md, San Jose Clinical Research, San Jose, CA; Paul A. Lehman, MS, University of Arka...

Objective: To investigate the child nutrition concerns of Aboriginal families with young children attending Aboriginal health and early childhood services in Victoria; training needs of early childhood practitioners; and sources of nutrition and child health information and advice for Aboriginal families with young children. Method:Qualitative needs assessment involving consultation with Aboriginal parents of young children aged 0-8 years attending Aboriginal health and early childhood services, and early childhood practitioners from Aboriginal health and early childhood services in urban and regional Victoria. Focus groups were conducted with 35 Aboriginal parents and interviews conducted with 45 health and early childhood practitioners. Thematic analysis was used to generate and then refine distinct, internally consistent common themes from the data. Results:The most frequent issues identified were low levels of breastfeeding, inappropriate introduction of solids, reliance on bottles, sweet drinks, and energy-dense foods, poor oral health and overweight. Concerns about staff training and capacity, and access to maternal and child health services were also common. Conclusion and implication:This study identifies major gaps in service delivery for Aboriginal families with young children and points to the need for a coordinated, culturally responsive systems approach to providing support for breastfeeding and child nutrition advice and support for Aboriginal families, including capacity building for staff, and supportive systems and policy.

With SDP, triptan users requiring a change in therapy experienced increased efficacy, satisfaction with therapy, and confidence in treatment without deterioration in tolerability.